LiquidCNA: Tracking subclonal evolution from longitudinal liquid biopsies using somatic copy number alterations.

Cancer Cancer systems biology Genomics

Journal

iScience
ISSN: 2589-0042
Titre abrégé: iScience
Pays: United States
ID NLM: 101724038

Informations de publication

Date de publication:
20 Aug 2021
Historique:
received: 20 04 2021
revised: 10 06 2021
accepted: 15 07 2021
entrez: 17 8 2021
pubmed: 18 8 2021
medline: 18 8 2021
Statut: epublish

Résumé

Cell-free DNA (cfDNA) measured via liquid biopsies provides a way for minimally invasive monitoring of tumor evolutionary dynamics during therapy. Here we present liquidCNA, a method to track subclonal evolution from longitudinally collected cfDNA samples sequenced through cost-effective low-pass whole-genome sequencing. LiquidCNA utilizes somatic copy number alteration (SCNA) to simultaneously genotype and quantify the size of the dominant subclone without requiring B-allele frequency information, matched-normal samples, or prior knowledge on the genetic identity of the emerging clone. We demonstrate the accuracy of liquidCNA in synthetically generated sample sets and

Identifiants

pubmed: 34401670
doi: 10.1016/j.isci.2021.102889
pii: S2589-0042(21)00857-9
pmc: PMC8350516
doi:

Types de publication

Journal Article

Langues

eng

Pagination

102889

Subventions

Organisme : Wellcome Trust
ID : 202778/Z/16/Z
Pays : United Kingdom
Organisme : Cancer Research UK
ID : A19771
Pays : United Kingdom
Organisme : NCI NIH HHS
ID : U54 CA217376
Pays : United States

Informations de copyright

© 2021 The Authors.

Déclaration de conflit d'intérêts

The authors declare no competing interest.

Références

Nat Med. 2019 May;25(5):738-743
pubmed: 31011204
Cancer Discov. 2018 Oct;8(10):1270-1285
pubmed: 30166348
Sci Transl Med. 2018 Nov 7;10(466):
pubmed: 30404863
Cancer Prev Res (Phila). 2014 Jan;7(1):114-27
pubmed: 24253313
PLoS One. 2011;6(9):e23418
pubmed: 21909401
Bioinformatics. 2014 Dec 15;30(24):3532-40
pubmed: 25297070
Gastroenterology. 1992 Nov;103(5):1611-20
pubmed: 1426881
JCI Insight. 2018 Nov 2;3(21):
pubmed: 30385733
Nat Med. 2020 Dec;26(12):1859-1864
pubmed: 33020649
Nature. 2017 Jun 15;546(7658):431-435
pubmed: 28607484
Bioinformatics. 2007 Mar 15;23(6):657-63
pubmed: 17234643
BMC Bioinformatics. 2016 Aug 19;17:310
pubmed: 27538789
Clin Cancer Res. 2017 May 1;23(9):2223-2231
pubmed: 27852697
Cancer Res. 2009 Jun 1;69(11):4894-903
pubmed: 19487300
Breast Cancer Res. 2019 Dec 19;21(1):149
pubmed: 31856868
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Nat Rev Cancer. 2018 Nov;18(11):696-705
pubmed: 30293088
Proc Natl Acad Sci U S A. 2020 Mar 3;117(9):4858-4863
pubmed: 32075918
Nat Commun. 2020 Sep 2;11(1):4301
pubmed: 32879317
Nat Commun. 2017 Nov 6;8(1):1324
pubmed: 29109393
PLoS Med. 2016 Dec 20;13(12):e1002198
pubmed: 27997533
PLoS Genet. 2016 Jul 18;12(7):e1006162
pubmed: 27428049
Nature. 2011 Jun 29;474(7353):609-15
pubmed: 21720365
Genome Res. 2014 Nov;24(11):1881-93
pubmed: 25060187
Nat Commun. 2020 Feb 13;11(1):822
pubmed: 32054838
Nature. 2012 Jun 28;486(7404):537-40
pubmed: 22722843
Genome Res. 2014 Dec;24(12):2022-32
pubmed: 25236618
Br J Cancer. 2020 Sep;123(6):982-987
pubmed: 32669676
Nat Rev Clin Oncol. 2018 Mar;15(3):139-150
pubmed: 29297505
Nature. 2010 Feb 18;463(7283):899-905
pubmed: 20164920
Nat Med. 2014 May;20(5):548-54
pubmed: 24705333
Cancer Res. 2015 Nov 15;75(22):4675-80
pubmed: 26527288
Clin Cancer Res. 2017 Oct 15;23(20):6305-6314
pubmed: 28710315
Eur J Cancer. 2017 Nov;86:186-196
pubmed: 28992562
Sci Transl Med. 2014 Feb 19;6(224):224ra24
pubmed: 24553385
Sci Rep. 2017 Jan 19;7:40737
pubmed: 28102343
Nat Commun. 2017 Nov 28;8(1):1816
pubmed: 29180633
Sci Transl Med. 2017 Aug 16;9(403):
pubmed: 28814544
Oncotarget. 2017 Sep 22;8(52):89848-89866
pubmed: 29163793
Clin Cancer Res. 2019 Apr 1;25(7):2254-2263
pubmed: 30617129
Exp Mol Pathol. 2018 Jun;104(3):161-169
pubmed: 29608913
Elife. 2018 Sep 04;7:
pubmed: 30178746
Adv Exp Med Biol. 2016;924:29-32
pubmed: 27753014
Cell Rep. 2014 Jun 12;7(5):1740-1752
pubmed: 24882004
Nat Rev Clin Oncol. 2017 Sep;14(9):531-548
pubmed: 28252003

Auteurs

Eszter Lakatos (E)

Centre for Genomics and Computational Biology, Barts Cancer Institute, Queen Mary University of London, London, UK.

Helen Hockings (H)

Centre for Cancer Cell and Molecular Biology, Barts Cancer Institute, Queen Mary University of London, London, UK.
Barts Health NHS Trust, St Bartholomew's Hospital, West Smithfield, London, UK.

Maximilian Mossner (M)

Centre for Genomics and Computational Biology, Barts Cancer Institute, Queen Mary University of London, London, UK.

Weini Huang (W)

School of Mathematical Sciences, Queen Mary University of London, London, UK.

Michelle Lockley (M)

Centre for Cancer Cell and Molecular Biology, Barts Cancer Institute, Queen Mary University of London, London, UK.
Department of Gynaecological Oncology, Cancer Services, University College London Hospital, London, UK.

Trevor A Graham (TA)

Centre for Genomics and Computational Biology, Barts Cancer Institute, Queen Mary University of London, London, UK.

Classifications MeSH